Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Ihnen/SKU | Verfügbarkeit | Preis |
|---|---|---|
5 mg | Warenkorb auf Verfügbarkeit prüfen | € 216,00 € 183,60 |
Über diesen Artikel
Empirische Formel (Hill-System):
C20H14ClN3O2 · xH2O
CAS-Nummer:
Molekulargewicht:
363.80 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
€ 183,60
Listenpreis€ 216,00Sparen Sie 15%Aktion nur im Web
Warenkorb auf Verfügbarkeit prüfen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Segment
assay
≥98% (HPLC)
form
solid
color
off-white to tan
solubility
DMSO: ≥2 mg/mL (warmed)
originator
Johnson & Johnson
storage temp.
2-8°C
SMILES string
O=C(C1=CC=C2C(N=C(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)N2)=C1)N
InChI
1S/C20H14ClN3O2/c21-14-4-8-16(9-5-14)26-15-6-1-12(2-7-15)20-23-17-10-3-13(19(22)25)11-18(17)24-20/h1-11H,(H2,22,25)(H,23,24)
InChI key
UXGJAOIJSROTTN-UHFFFAOYSA-N
Gene Information
human ... CHEK2(11200)
Biochem/physiol Actions
Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer.
Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer. IC50 = 15 nM; Ki = 37 nM. Chk2 Inhibitor II shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC50 = 12 μM and 17 μM, respectively). Chk2 Inhibitor II weakly inhibits a panel of 31 other kinases (<25% inhibition at a concentration of 10 μM and prevents apoptosis of human CD4+ and CD8+ T-cells subjected to ionizing radiation (EC50 = 3 μM and 7.6 μM, respectively).
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| form solid | form solid | form solid | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥95% (HPLC) | assay >98% (HPLC) |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: ≥2 mg/mL (warmed) | solubility DMSO: ≥12 mg/mL | solubility DMSO: 5 mg/mL | solubility DMSO: 10 mg/mL, clear |
| color off-white to tan | color white to beige | color pale yellow | color white to beige |
Lagerklasse
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.



